Drug intelligence / Profile preview

hydroxychloroquine + vorinostat

Development stage: Unknown
Lead developer: University of Texas Health Science Center at San Antonio
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of hydroxychloroquine (HCQ) and vorinostat (VOR). Hydroxychloroquine functions as an autophagy inhibitor while vorinostat is a histone deacetylase (HDAC) inhibitor. This combination has been investigated primarily for metastatic colorectal cancer (mCRC) and HIV. The dual mechanism of action leads to autophagy inhibition, accumulation of ubiquitinated proteins, subsequent tumor cell apoptosis, and improved anti-tumor immunity.

Brand names: ZolinzaPlaquenil
Other names: HCQhydroxychloroquinevorinostatSAHAVorinostat and HydroxychloroquineHCQ + Vorinostat

Targets

HDAC6 (Histone deacetylase 6)HDAC1 (Histone Deacetylase 1)PPT1 (Palmitoyl-protein thioesterase 1)

Beyond the preview

Go deeper on hydroxychloroquine + vorinostat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hydroxychloroquine + vorinostat.

Explore the full profile